REGN - Regeneron Pharmaceuticals, Inc.

REGN

$797.00 11.05 (-1.37%)

After Hours: $797.00 +0.00 (+0.00%)

Last updated: Aug 11, 2026 20:55

52-Week Range

$797.00

$541.00 $797.00 $821.11

Fundamentals Overview

Regeneron Pharmaceuticals, Inc. is near the high of its 52-week range with moderate valuation, trading relatively flat today.

Valuation moderate

P/E 19.7 P/B 2.6 P/S 5.29

Intrinsic value (DCF)

+179% upside vs price

Profitability

Net margin 27.9%

Risk (Beta)

0.24 — lower vol

Earnings & growth

EPS $40.53 Rev +19% Profit +78.3% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell

Buy

Hold — 65% confidence Risk: Lower Volatility — Beta 0.24. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +179% upside vs price · Analyst grade: A · 3M vs S&P 500: +7%

Pressures (Sell):

Sentiment weakening (2 downgrades) · 3M vs Healthcare sector: -5.6%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap

$82.11B

P/E (TTM)

19.66

EPS (TTM)

$40.53

Dividend Yield

0.46%

52-Week Range

$541.00 - $821.11

Volume vs Avg

N/A

Beta

0.24

About

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both ce...

Sector: Healthcare

Headquarters: US

Employees: 15,410

IPO Date: Apr 1991

Website: www.regeneron.com

Beta: 0.24 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: A. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 10, Equal Weight: 6, Market Perform: 1, Neutral: 1, Outperform: 1, Overweight: 7, Sector Perform: 4.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $2,223.49; current price is $797.00. That’s a +179% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric	Value
Valuation
P/E (TTM)	19.66
DCF value (model)	$2,223.49 (179% upside)
PEG (TTM)	N/A
P/B (TTM)	2.6
P/S (TTM)	5.29
P/FCF (TTM)	23.31
Liquidity & enterprise
Current Ratio (TTM)	3.34
Quick Ratio (TTM)	2.78
Cash Ratio (TTM)	0.44
Profitability
ROE (TTM)	N/A
ROA (TTM)	N/A
Revenue growth (YoY)	N/A
Net margin (TTM)	27.86%
Gross margin (TTM)	84.86%
Operating margin (TTM)	25.56%
Debt to equity (TTM)	N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for REGN.

Analyst Sentiment at a Glance

A Sentiment Weakening

Buy 10Equal Weight 6Market Perform 1Neutral 1Outperform 1Overweight 7Sector Perform 4

1 upgrade, 2 downgrades

Price Target Consensus

Current $797.00

Median $800.00

Consensus $819.59

Low consensus $641.00

High consensus $1,030.00

Stock Grades (Institutions)

Institution	Action	Previous Grade	New Grade	Date
Truist Securities	maintain	Buy	Buy	2026-07-31
Morgan Stanley	maintain	Equal Weight	Equal Weight	2026-07-31
Cantor Fitzgerald	maintain	Overweight	Overweight	2026-07-31
Wells Fargo	maintain	Equal Weight	Equal Weight	2026-07-31
RBC Capital	maintain	Sector Perform	Sector Perform	2026-07-31
Guggenheim	maintain	Buy	Buy	2026-07-21
Piper Sandler	maintain	Overweight	Overweight	2026-07-09
Morgan Stanley	maintain	Equal Weight	Equal Weight	2026-07-08
RBC Capital	maintain	Sector Perform	Sector Perform	2026-07-07
Truist Securities	maintain	Buy	Buy	2026-07-07
Benchmark	upgrade	Hold	Buy	2026-07-07
HSBC	maintain	Buy	Buy	2026-07-06
Cantor Fitzgerald	maintain	Overweight	Overweight	2026-07-06
Canaccord Genuity	maintain	Buy	Buy	2026-05-19
BMO Capital	maintain	Outperform	Outperform	2026-05-18
Truist Securities	maintain	Buy	Buy	2026-05-18
JP Morgan	maintain	Overweight	Overweight	2026-05-18
Piper Sandler	maintain	Overweight	Overweight	2026-05-18
Wells Fargo	maintain	Equal Weight	Equal Weight	2026-05-18
RBC Capital	maintain	Sector Perform	Sector Perform	2026-05-18
Citigroup	downgrade	Buy	Neutral	2026-05-18
Leerink Partners	downgrade	Outperform	Market Perform	2026-05-18
Guggenheim	maintain	Buy	Buy	2026-05-01
RBC Capital	maintain	Sector Perform	Sector Perform	2026-04-30
Barclays	maintain	Overweight	Overweight	2026-04-30
Truist Securities	maintain	Buy	Buy	2026-04-30
Wells Fargo	maintain	Equal Weight	Equal Weight	2026-04-30
TD Cowen	maintain	Buy	Buy	2026-04-23
Cantor Fitzgerald	maintain	Overweight	Overweight	2026-04-23
Morgan Stanley	maintain	Equal Weight	Equal Weight	2026-04-10